Your Article Summary
See Latest ArticlesPhase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
European Journal of Cancer, 06/15/09
Vergote I et al. - Canfosfamide HCl (CAN; a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis) was well tolerated in pts with platinum-refractory or -resistant ovarian cancer (OC).
Methods- Pts with platinum-refractory or -resistant OC who had progressed on second-line therapy with pegylated liposomal doxorubicin (PLD) or topotecan (TOPO), were randomized to:
- CAN 1000 mg/m2 IV q 3 weeks or
- Either PLD 50 mg/m2 IV q 4 wks or TOPO 1.5 mg/m2 IV d1-5 q 3 wks
- 461 pts were randomised after stratification for ECOG performance status, prior therapy, and bulky (>5 cm) disease
- Groups were well balanced
- In the control arm 58% and 42% were treated with PLD and TOPO, respectively
- CAN was well tolerated with the most common grade 3-4 toxicities of 5% anaemia, 4% neutropaenia (no febrile neutropaenia), 4% thrombocytopaenia, and 7% vomiting
- PFS and OS were higher in the control arm
- In a subgroup analysis PFS and OS were higher with PLD than with TOPO
Related Articles
Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer
Cancer Letters, 12/04/09
Relevance Score: 70%%
Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival
British Journal of Cancer, 11/30/09
Relevance Score: 70%%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 70%%
Breast-feeding the last born child and risk of ovarian cancer
Cancer Causes and Control, 11/16/09
Relevance Score: 69%%
Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review
Critical Reviews in Oncology/Hematology, 11/12/09
Relevance Score: 69%%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/04/09
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Vaginal Schwannoma in a case with uterine myoma
Annals of Diagnostic Pathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09